Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | GPR88 | Q9GZN0 | 5/20 | 0.39 |
| ▸ | XIAP | P98170 | 4/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3343067 | 0.83 | ACE (0.50) | ACEMMECTSBCTSSCTSK | |
| SCHEMBL3341491 | 0.77 | PSEN1 (0.46) | ACEMME | |
| SCHEMBL3346941 | 0.72 | ACE (0.40) | ACEMMEMEN1KMT2ACCKBR | |
| SCHEMBL3343100 | 0.72 | ACE (0.42) | ACEMMECTSBCTSSCTSK | |
| SCHEMBL3340791 | 0.68 | PSEN1 (0.56) | ACEMME | |
| SCHEMBL3343191 | 0.66 | PSEN1 (0.45) | ACEMME | |
| SCHEMBL6211227 | 0.66 | PSEN1 (0.45) | ACEMME | |
| SCHEMBL3342540 | 0.64 | PSEN1 (0.42) | ACEMMEMEN1KMT2A | |
| SCHEMBL3343313 | 0.63 | HSD17B10 (0.50) | ACEMMEMEN1KMT2A | |
| SCHEMBL3346896 | 0.63 | HSD17B10 (0.50) | ACEMMEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089346-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089346-A1 | Novel lactams and uses thereof | BACE1, BACE2, APH1B | ACE 139/4885MME 345/4885GPR88 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.